Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Director · President and CEO | August 21, 2020 | June 11, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date August 21, 2020 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.83 · Expires 2030-08-20 | IndirectBy Spouse | 1,743 |
Reported balance
After 2020-08-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-08-21 · Grant · Acquired 1,743 · Balance 1,743 F1: The option vests as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. F2: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date.
F2: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 07, 2021 Filed Jun 9, 2021 22:37 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 763 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039278 · doc4.xml · derivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 763 Underlying: Common Stock · 763 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F4 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F4 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F2 · ownership.nature: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:37 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,312 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039278 · doc4.xml · derivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. F2 · ownership.nature: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:50 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-032773 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:50 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,675 | $8.96 | $86,688.00 |
DisclosureSEC source: 0001209191-21-032773 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,013,597 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.96 to $9.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 13, 2021 Filed May 14, 2021 20:50 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-032773 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:27 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,514 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:27 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,746 | $8.25 | $80,404.50 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,001,758 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.31. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:27 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,011,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:27 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,028 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:27 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,742 | $8.57 | $83,488.94 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,989,990 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| May 07, 2021 Filed May 11, 2021 20:27 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-031670 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,999,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 13,422 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001209191-21-028105 · doc4.xml · derivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,422 shares Expires 2027-03-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 21, 2021 Filed Apr 23, 2021 20:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 13,422 | $1.18 | $15,837.96 |
DisclosureSEC source: 0001209191-21-028105 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,978,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:37 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026663 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,542 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:37 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,741 | $8.67 | $84,454.47 |
DisclosureSEC source: 0001209191-21-026663 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964,796 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 20:37 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-026663 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,056 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,737 | $8.87 | $86,367.19 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,953,023 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 09, 2021 Filed Apr 12, 2021 21:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 21:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,570 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 21:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,736 | $9.00 | $87,624.00 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,941,246 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| April 08, 2021 Filed Apr 12, 2021 21:06 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-026375 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,950,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:34 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020823 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,084 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:34 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,712 | $11.36 | $110,328.32 |
DisclosureSEC source: 0001209191-21-020823 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,929,468 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.36 to $11.38. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:34 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-020823 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,939,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,598 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,711 | $11.38 | $110,511.18 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,917,666 F2 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 23:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,927,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,112 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,710 | $11.79 | $114,480.90 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,905,863 F2 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.61 to $11.80. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 23:03 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-020273 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,915,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,613 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on February 22, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:45 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-012745 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,626 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:45 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,705 | $12.23 | $118,692.15 |
DisclosureSEC source: 0001209191-21-012745 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,446 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:45 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-012745 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,899,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-011888 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,140 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,705 | $12.28 | $119,177.40 |
DisclosureSEC source: 0001209191-21-011888 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,877,637 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-011888 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,887,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-011888 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,654 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,697 | $13.30 | $128,970.10 |
DisclosureSEC source: 0001209191-21-011888 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,865,828 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:44 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-011888 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,875,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,515 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-005870 · doc4.xml · derivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,168 Underlying: Common Stock · 21,515 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,697 | $13.37 | $129,648.89 |
DisclosureSEC source: 0001209191-21-005870 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854,011 F1 · kind: All sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.33 to $13.47. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,515 | $0.04 | $860.60 |
DisclosureSEC source: 0001209191-21-005870 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,863,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:56 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-005395 · doc4.xml · derivative · entry 7 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,683 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:56 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 9,695 | $13.74 | $133,209.30 |
DisclosureSEC source: 0001209191-21-005395 · doc4.xml · nonDerivative · entry 4 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,842,193 F2 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise for an option grant expiring 05/17/2021, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $13.86. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:56 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-005395 · doc4.xml · nonDerivative · entry 3 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,851,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:56 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 21,514 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001209191-21-005395 · doc4.xml · derivative · entry 6 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,197 Underlying: Common Stock · 21,514 shares Expires 2021-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:56 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | SaleCommon Stock | 10,218 | $13.53 | $138,249.54 |
DisclosureSEC source: 0001209191-21-005395 · doc4.xml · nonDerivative · entry 2 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830,374 F2 · kind: The sales were effected pursuant to a Rule 10b5-1 plan. The transaction was a sell-to-cover exercise for an option grant expiring 05/17/2021, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.60. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 21:56 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 21,514 | $0.04 | $860.56 |
DisclosureSEC source: 0001209191-21-005395 · doc4.xml · nonDerivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,840,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 6,651 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the reporting person's ownership report filed on September 25, 2019. Read SEC document |
| August 21, 2020 Filed Jun 11, 2021 21:00 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,743 | $0.00 Strike: $5.83 | $0.00 |
DisclosureSEC source: 0001209191-21-039902 · doc4.xml · derivative · entry 1 KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 1,743 Underlying: Common Stock · 1,743 shares Expires 2030-08-20 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2021 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. F2 · ownership.nature: Employee Stock Option is held by Chelsea Lynam Kane, the spouse of the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.